News + Filings Transactions Holdings
All
13F
13D/G
Other
|
|
RA CAPITAL MANAGEMENT, L.P.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 4.6% stake in SOLENO THERAPEUTICS, INC. |
| 09/29/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 7.3% stake in CHIMERIX, INC. |
| 08/25/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in TAYSHA GENE THERAPIES, INC. |
| 08/22/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Bought 1,777,778 shares
@ $9, valued at
$16M
|
|
| 08/21/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in GRACELL BIOTECHNOLOGIES INC. |
| 08/17/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 9.8% stake in NEKTAR THERAPEUTICS |
| 08/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Bellus Health Inc. |
| 08/14/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Kinnate Biopharma Inc. |
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/11/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 33.7% stake in VOR BIOPHARMA INC. |
| 08/11/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 16.7% stake in 89BIO, INC. |
| 08/09/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Wave Life Sciences Ltd.|
Txns:
| Granted 45,000 options to buy
@ $4.58, valued at
$206.1k
|
|
| 08/09/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (Former 10% owners and Director) has filed a Form 4 on DICE Therapeutics, Inc.|
Txns:
| Unknown transaction of 7,070,205 shares
@ $0
Unknown transaction of 786,407 shares
@ $0
Disposed/sold 21,250 options to buy
@ $14.98, valued at
$318.3k
|
|
| 08/09/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in DICE THERAPEUTICS, INC. |
| 08/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 07/25/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 07/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/07/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (Director) has filed a Form 4 on Black Diamond Therapeutics, Inc.|
Txns:
| Bought 935,850 shares
@ $5, valued at
$4.7M
|
|
| 07/06/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 5.5% stake in TALARIS THERAPEUTICS, INC. |
| 07/06/2023 |
SC 13G
| RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in UNICYCIVE THERAPEUTICS, INC. |
| 06/28/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (Director) has filed a Form 4 on ARS Pharmaceuticals, Inc.|
Txns:
| Granted 40,000 options to buy
@ $6.5, valued at
$260k
|
|
| 06/16/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 12,500 options to buy
@ $13.22, valued at
$165.3k
|
|
| 06/12/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (Former 10% Owner) has filed a Form 4 on Satsuma Pharmaceuticals, Inc.|
Txns:
| Unknown transaction of 5,914,252 shares
@ $0
Disposed/sold 10,000 options to buy
@ $26.99, valued at
$269.9k
Disposed/sold 20,000 options to buy
@ $4.6, valued at
$92k
Disposed/sold 30,000 options to buy
@ $3.46, valued at
$103.8k
|
|
| 06/12/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in Satsuma Pharmaceuticals, Inc. |
| 06/09/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Nkarta, Inc.|
Txns:
| Granted 22,500 options to buy
@ $4.86, valued at
$109.4k
|
|
| 06/08/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Aerovate Therapeutics, Inc.|
Txns:
| Granted 12,500 options to buy
@ $16.3, valued at
$203.8k
|
|
| 06/08/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Solid Biosciences Inc.|
Txns:
| Granted 9,650 options to buy
@ $6.37, valued at
$61.5k
|
|
| 06/08/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Icosavax, Inc.|
Txns:
| Granted 17,000 options to buy
@ $9.89, valued at
$168.1k
|
|
| 06/02/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 30,000 options to buy
@ $4.79, valued at
$143.7k
|
|
| 06/02/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Tyra Biosciences, Inc.|
Txns:
| Granted 14,500 options to buy
@ $14.47, valued at
$209.8k
|
|
| 05/30/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 12.5% stake in Icosavax, Inc. |
| 05/15/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in TRAVERE THERAPEUTICS, INC. |
| 05/15/2023 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in DA32 Life Science Tech Acquisition Corp. |
|
|
|